Market Overview

Sterne Agee Raises Actavis plc Estimates, Price Target

White House Budget To Support Biotech Rally
Citigroup Ponders How Results From Namenda Survey Might Affect Actavis
FDA clears abuse-deterrent formulation of Zohydro (Seeking Alpha)

Following a meeting with Actavis’ management, analysts at Sterne Agee increased the earnings estimates and price target on Actavis plc (NYSE: ACT).

Analyst Shibani Malhotra stated,”we raise the price target from $255 to $272 and remain buyers of Actavis on a fundamental basis.”

Analysts also raised third and fourth quarter 2014 earnings estimates to $3.03 per share and $3.41 per share.

Full year 2014 EPS estimates were raised to $13.25 from $13.02.

In addition, Actavis's Watson Labs Dorzolamide Hydrochloride, Timolol, Maleate ANDA was approved by the FDA.

Shares of Actavis are traded recently at $231.01, up 1.08 percent.

Latest Ratings for ACT

Jan 2015Deutsche BankMaintainsBuy
Jan 2015Deutsche BankMaintainsBuy
Dec 2014Morgan StanleyMaintainsOverweight

View More Analyst Ratings for ACT
View the Latest Analyst Ratings

Posted-In: Shibani Malhotra Sterne AgeeAnalyst Color Price Target Analyst Ratings


Related Articles (ACT)

Around the Web, We're Loving...

Get Benzinga's Newsletters